News

GlobalData on MSN8h
Nektar’s stock doubles on eczema therapy success in Phase IIb study
Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...
Zacks.com on MSN9h
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Nektar surges as lead asset succeeds in mid-stage trial for eczema
Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...
Fierce Biotech11h
Investors sweet on Nektar as phase 2b eczema success doubles share price
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...
BioPharma Dive2h
FDA investigating Elevidys safety; Nektar shares spike on eczema data
The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...
How big data and big deals may lead comebacks for Bay Area biotechs
New player emerges in 23andMe bankruptcy An Indian drug company has big plans for the East Bay An Indian drug company has big ...
Nektar Therapeutics Atopic Dermatitis Treatment Meets Primary Endpoint
The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...
Investor's Business Daily on MSN11h
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam
Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema ...